12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersImmutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million. Syra Health (NASDAQ:SYRA) stock
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Kiora Pharmaceuticals Secures Grant for Vision Test Validation
Kiora Pharmaceuticals Receives Grant From Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validati
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
Kiora Pharmaceuticals to Present Additional Data From Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accept
Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Maintains $2 Price Target
HC Wainwright & Co. analyst Yi Chen maintains Kiora Pharmaceuticals with a Buy and maintains $2 price target.
Kiora Pharmaceuticals Reports FY Results
Kiora Pharma Reported Q4 Net Loss of $(2.3)M, Cash Balance of $2.5M
Kiora Pharma Reported Q4 Net Loss of $(2.3)M, Cash Balance of $2.5M
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the
A Look Into Healthcare Sector Value Stocks
Understanding Value StocksA value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indica
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the publication of results from a Phase 1 double-masked study
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersAinos (NASDAQ:AIMD) shares moved upwards by 100.0% to $2.24 during Thursday's after-market session. The market value of their outstanding shares is at $10.4 million. Talphera (NASDAQ:TLPH) stoc
Kiora Pharmaceuticals Files to Sell 76.53M Shares of Common Stock for Holders
5 Value Stocks In The Healthcare Sector
The Meaning Behind Value StocksA value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as inv
Kiora Pharmaceuticals Unveils Updated Investor Presentation
Kiora Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Kiora Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Adjusts Price Target To $2
HC Wainwright & Co. analyst Yi Chen maintains Kiora Pharmaceuticals with a Buy, adjusts target to $2 from $3.5.
No Data